0
New
New
2023
Wound Care Biologics Market

Wound Care Biologics Market

By Product (Biological Skin Substitutes, Topical Agents), By Wound Type (Acute Wound, Chronic Wound), By End User (Hospitals and Clinics, Wound Centers and Burn Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A10347
Jul 2023 | Pages: 255
Tables: 130
Charts: 63
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Wound Care Biologics Market Research, 2032

The global wound care biologics market size was valued at $1.8 billion in 2022, and is projected to reach $3.3 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to a category of advanced therapies and products used in the management and treatment of various types of wounds. These biologics are derived from living organisms, such as human cells, animal tissues, or microorganisms, and are designed to facilitate the healing process, promote tissue regeneration, and enhance wound closure. These biologics are used in diabetic foot ulcer, venous leg ulcer, pressure ulcer, surgical and accidental wounds. 

The COVID-19 pandemic had a negative impact on the growth of the wound care biologics market, as it disrupted supply chains, led to delays in diagnosis and treatment, and decreased patient visits to healthcare facilities.

Wound Care Biologics Market

Market Dynamics

The major factors driving the growth of the wound biologics market are the increase in prevalence of chronic wounds such as diabetic foot ulcer, rise in geriatric population, and rise in advancements in wound care management products. The surge in prevalence of diabetes is a significant driver for the wound care biologics market share. For instance, as per National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC) in 2022, 130 million adults living with the diabetes or prediabetes in the U.S. Thus, rise in prevalence of diabetes led to increase in the demand for wound care biologic products. 

The advancements in wound care technologies such as development of biologic-based therapies, have significantly contributed toward the wound care biologics market share growth. Innovations such as growth factors, cellular matrices, tissue-engineered products, and extracellular vesicles have improved wound healing outcomes and provided new treatment options for complex wounds that support the market growth. For instance, Osiris Therapeutics, a part of Smith & Nephew plc developed Grafix, a cryopreserved placental membrane product. Grafix contains an intact extracellular matrix and a variety of growth factors, cytokines, and other bioactive components. This product has advanced minimally manipulative processing methods that preserve the native properties and components of fresh placental membranes. Such advanced features of wound care biologic product support the wound care biologics market growth. 

In addition, the aging population is prone to chronic wounds due to factors such as reduced mobility, compromised immune systems, and underlying health conditions. As people age, their skin becomes thinner, less elastic, and more fragile. This makes it more susceptible to damage and slower to heal, increasing the risk of developing chronic wounds. Thus, rise in the geriatric population provide the wound care biologics market opportunity . 

The growth of the wound biologics market is expected to be driven by high potential in untapped, emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic diseases, and surge in demand for advanced wound care biologic products. The demand for wound care biologics is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the wound care biologics market.  

Wound care biologics are more expensive than traditional wound care treatments. The production, development, and manufacturing processes involved in creating biologic-based therapies contribute to their higher cost. The high cost may pose a financial burden on healthcare systems, insurers, and patients, limiting their accessibility and adoption which negatively impacted the market growth. In addition, insufficient education and awareness about these therapies lead to underutilization or suboptimal use which hinders the market growth. 

The outbreak of the COVID-19 pandemic had a significant impact on various sectors, including the healthcare industry. The global wound care biologics market, including wound care biologics, experienced a decline in 2020 due to the global economic recession caused by the pandemic. The temporary closure of healthcare facilities and disruptions in workflows contributed to this decline. Many non-urgent medical procedures, including wound care, were delayed or canceled during the height of the pandemic. Patients faced challenges in accessing healthcare facilities, leading to reduced patient visits for wound care and delays in receiving appropriate treatments, including wound care biologics. 

However, the wound care biologics market recovered after the pandemic and is expected to show stable growth in the future. This is attributed to the increase in prevalence of chronic wounds, advancements in wound care biologics products and surge in awareness among healthcare professionals and patients about the benefits and applications of wound care biologics.

Segmental Overview 

The wound care biologics industry is segmented into product, wound type, end user, and region. By product, the market is categorized into biological skin substitutes and topical agents. On the basis of wound type, the market is segregated into acute wound and chronic wound. The acute segment further categorized into the burns and trauma, accidental and surgical. The chronic segment further categorized into the pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is classified into hospitals & clinics, homecare settings, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

By Product  

The biological skin substitute segment dominated the global market in 2022 and is expected to register the highest CAGR during the forecast period, owing to the increase in prevalence of chronic wounds and the surge in number of burn and trauma cases. In addition, advancements in biotechnology and tissue engineering enhances the development of biological skin substitutes, which further supports the segment growth.

Wound Care Biologics Market

By Wound Type

The chronic wound segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to the rise in incidence of chronic diseases such as diabetes and lifestyle factors contribute to the rise in prevalence of chronic wounds. This drives the demand for effective wound care solutions, leading to the dominance of the chronic wound segment in the market.

Wound Care Biologics Market

By End User

The hospitals and clinics held the largest wound care biologics market size in 2022 and is expected to remain dominant throughout the forecast period, owing to presence of specialized healthcare professionals, advanced infrastructure, collaborative healthcare services, centralized procurement, and reimbursement support contribute to their segmental growth.

Wound Care Biologics Market

By Region

The wound care biologics industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major share of the wound care biologics market in 2022 and is expected to maintain its dominance during the forecast period. 

The presence of several major players, such as Integra LifeSciences Holdings Corporation, Smith & Nephew plc, and Stryker Corporation and advancement in manufacturing technology of wound care biologics in the region drive the growth of the market. In addition, the presence of well-established healthcare infrastructure, high purchasing power, and rise in adoption rate of advanced wound care biologics are expected to drive the market growth. Furthermore, product launch, product approval, and acquisitions adopted by the key players in this region boost the growth of the market.  

Wound Care Biologics Market

Asia-Pacific is expected to grow at the highest rate during the wound care biologics market forecast period. The market growth in this region is attributable to purchasing power of populated countries, such as China and India. In addition, rise in the prevalence of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers due to aging population, increasing incidence of diabetes, and changes in lifestyle contribute to the growing burden of chronic wounds and creating a demand for advanced wound care solutions. Moreover, growing awareness among healthcare professionals and patients about the benefits of biologic-based wound care therapies is contributing to market growth. 

Asia-Pacific offers profitable opportunities for key players operating in the wound care biologics market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries as well as well-established presence of domestic companies in the region. Furthermore, the establishment of comprehensive wound care centers, advancements in diagnostic technologies, and access to modern treatment modalities drive the wound care biologics market. 

Competition Analysis

Competitive analysis and profiles of the major players in the wound care biologics, such as Bioventus, ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, MIMEDX Group, Inc., ORGANOGENESIS HOLDINGS INC., Skye Biologics Holdings, LLC, Smith+Nephew, and Tissue Regenix Group Plc. are provided in this report.

There are some important players in the market such as Lavior Pharma Inc. and others. Major players have adopted agreement, product launch, geographical expansion and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.

Recent Product Launches in the Wound Care Biologics Market 

  • In September 2022, MiMedx Group, Inc., a transformational placental biologics company, announced the launch of AXIOFILL, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. 
  • In September 2022, MiMedx Group, Inc., a transformational placental biologics company, announced the launch of AMNIOEFFECT, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta. 

Recent Product Approval in the Wound Care Biologics Market 

  • In March 2023, Convatec received clearance from the U.S. Food and Drug Administration for its InnovaBurn placental extracellular matrix medical device for management of complex surgical wounds and burns, including partial-thickness second-degree burns. 

Recent Agreements in the Wound Care Biologics Market 

  • In January 2023, MiMedx Group, Inc., a leader in placental biologics, announced that it has entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED, a subsidiary of Gunze Limited, for sales of EPIFIX in Japan. 
  • In December 2022, MiMedx Group, Inc., a leader in placental biologics announced an agreement with Turn Therapeutics. This agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion proprietary antimicrobial intellectual property (IP) and utilize the PermaFusion platform in the development of future biologic products, with a specific focus on applications related to wound healing and surgical recovery. 

Recent Geographical Expansion in the Wound Care Biologics Market 

  • In June 2023, Convatec opens new global headquarters in London. This relocation of Convatec headquarter forms part of a wider strategic review of its property footprint globally to create a productive working environment and enhance the employee experience. The new facility is designed to support the company's growth plans and provide a modern and collaborative workspace for employees.

Recent Acquisitions in the Wound Care Biologics Market 

  • In November 2020, Stryker Corporation announced that it has completed the acquisition of Wright Medical Group N.V., a global medical device company focused on extremities and biologics. This acquisition strengthens its global market position in the field of trauma and extremities and creating substantial opportunities to drive innovation. 
  • In October 2021, Bioventus Inc., a global leader in innovations for active healing, announced the acquisition of Misonix, a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. 
  • In March 2022, Convatec Group Plc is pleased to be announced that it has completed the acquisition of Triad Life Sciences Inc. The Triad, current portfolio and product pipeline transition expected to Convatec Advanced Wound Care (AWC) business and be known as Convatec Advanced Tissue Technologies.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.

Wound Care Biologics Market Report Highlights

Aspects Details
Market Size By 2032 USD 3.3 billion
Growth Rate CAGR of 6.1%
Forecast period 2022 - 2032
Report Pages 255
By Wound Type
  • Acute Wound
    • Type
      • Burns and Trauma
      • Surgical
  • Chronic Wound
    • Type
      • Pressure Ulcer
      • Diabetic Ulcer
      • Venous Ulcer
      • Others
By End User
  • Hospitals and Clinics
  • Wound Centers and Burn Centers
  • Others
By Product
  • Biological Skin Substitutes
    • Type
      • Human Donor Tissue Derived Products
      • Animal Derived Products
      • Cell Based Bioengineered Products
  • Topical Agents
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Skye Biologics Holdings, LLC, Kerecis, Stryker Corporation., Tissue Regenix Group Plc, Integra LifeSciences Holdings Corporation, MIMEDX Group, Inc., Smith & Nephew plc, ConvaTec Group plc, Lavior Pharma Inc., ORGANOGENESIS HOLDINGS INC.

Analyst Review

This section provides various opinions in the wound care biologics market. The increase in prevalence of chronic wounds, rise in aging population, and the surge in demand for advanced wound care solutions provide a favorable market landscape. In addition, surge in investments for developing advanced wound care products globally is expected to offer profitable opportunities for the expansion of the market. However, the high cost of wound care biologics products and strict regulations for the manufacturing wound care biologics are expected to limit the market growth.

In addition, the surge in cases of diabetic patients as well as increase in prevalence of chronic wounds such as pressure ulcer, diabetic foot ulcers, venous leg ulcers, arterial ulcers, increase in number of patients undergoing surgeries, and rise in geriatric population are expected to drive the growth of the wound care biologics market.

Furthermore, North America is expected to witness the largest growth, in terms of revenue, owing to the surge in geriatric population suffering from chronic diseases, rise in prevalence of acute & chronic wounds in the region, and presence of developed infrastructure in the healthcare industry. However, Asia-Pacific is anticipated to witness notable growth owing to increase in prevalence of chronic wounds, surge in healthcare expenditure, advancements in wound care biologics to develop novel products, and a large patient population.? 

 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Moderate bargaining power of suppliers

      • 3.3.2. Moderate threat of new entrants

      • 3.3.3. Moderate threat of substitutes

      • 3.3.4. Moderate intensity of rivalry

      • 3.3.5. Moderate bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Growing burden of burn injuries and road accidents
        • 3.4.1.2. Surge in incidences of chronic diseases and surgeries
        • 3.4.1.3. Advancements in wound care management

      • 3.4.2. Restraints

        • 3.4.2.1. High cost of wound care biologics
        • 3.4.2.2. Stringent regulations for manufacturing of wound care products

      • 3.4.3. Opportunities

        • 3.4.3.1. Growth opportunities in emerging markets

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: WOUND CARE BIOLOGICS MARKET, BY PRODUCT

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Biological Skin Substitutes

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

      • 4.2.4. Biological Skin Substitutes Wound Care Biologics Market by Type

    • 4.3. Topical Agents

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

  • CHAPTER 5: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Acute Wound

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

      • 5.2.4. Acute Wound Wound Care Biologics Market by Type

    • 5.3. Chronic Wound

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

      • 5.3.4. Chronic Wound Wound Care Biologics Market by Type

  • CHAPTER 6: WOUND CARE BIOLOGICS MARKET, BY END USER

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospitals and Clinics

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Wound Centers and Burn Centers

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Others

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

  • CHAPTER 7: WOUND CARE BIOLOGICS MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Product

      • 7.2.3. Market size and forecast, by Wound Type

      • 7.2.4. Market size and forecast, by End User

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Product
          • 7.2.5.1.3. Market size and forecast, by Wound Type
          • 7.2.5.1.4. Market size and forecast, by End User
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Product
          • 7.2.5.2.3. Market size and forecast, by Wound Type
          • 7.2.5.2.4. Market size and forecast, by End User
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Product
          • 7.2.5.3.3. Market size and forecast, by Wound Type
          • 7.2.5.3.4. Market size and forecast, by End User
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Product

      • 7.3.3. Market size and forecast, by Wound Type

      • 7.3.4. Market size and forecast, by End User

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Product
          • 7.3.5.1.3. Market size and forecast, by Wound Type
          • 7.3.5.1.4. Market size and forecast, by End User
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Product
          • 7.3.5.2.3. Market size and forecast, by Wound Type
          • 7.3.5.2.4. Market size and forecast, by End User
        • 7.3.5.3. UK
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Product
          • 7.3.5.3.3. Market size and forecast, by Wound Type
          • 7.3.5.3.4. Market size and forecast, by End User
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Product
          • 7.3.5.4.3. Market size and forecast, by Wound Type
          • 7.3.5.4.4. Market size and forecast, by End User
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Product
          • 7.3.5.5.3. Market size and forecast, by Wound Type
          • 7.3.5.5.4. Market size and forecast, by End User
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Product
          • 7.3.5.6.3. Market size and forecast, by Wound Type
          • 7.3.5.6.4. Market size and forecast, by End User
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Product

      • 7.4.3. Market size and forecast, by Wound Type

      • 7.4.4. Market size and forecast, by End User

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Product
          • 7.4.5.1.3. Market size and forecast, by Wound Type
          • 7.4.5.1.4. Market size and forecast, by End User
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Product
          • 7.4.5.2.3. Market size and forecast, by Wound Type
          • 7.4.5.2.4. Market size and forecast, by End User
        • 7.4.5.3. India
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Product
          • 7.4.5.3.3. Market size and forecast, by Wound Type
          • 7.4.5.3.4. Market size and forecast, by End User
        • 7.4.5.4. Australia
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Product
          • 7.4.5.4.3. Market size and forecast, by Wound Type
          • 7.4.5.4.4. Market size and forecast, by End User
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Product
          • 7.4.5.5.3. Market size and forecast, by Wound Type
          • 7.4.5.5.4. Market size and forecast, by End User
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Product
          • 7.4.5.6.3. Market size and forecast, by Wound Type
          • 7.4.5.6.4. Market size and forecast, by End User
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Product

      • 7.5.3. Market size and forecast, by Wound Type

      • 7.5.4. Market size and forecast, by End User

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Product
          • 7.5.5.1.3. Market size and forecast, by Wound Type
          • 7.5.5.1.4. Market size and forecast, by End User
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Product
          • 7.5.5.2.3. Market size and forecast, by Wound Type
          • 7.5.5.2.4. Market size and forecast, by End User
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Product
          • 7.5.5.3.3. Market size and forecast, by Wound Type
          • 7.5.5.3.4. Market size and forecast, by End User
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Product
          • 7.5.5.4.3. Market size and forecast, by Wound Type
          • 7.5.5.4.4. Market size and forecast, by End User
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Integra LifeSciences Holdings Corporation

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

    • 9.2. Kerecis

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

    • 9.3. MIMEDX Group, Inc.

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

      • 9.3.7. Key strategic moves and developments

    • 9.4. ORGANOGENESIS HOLDINGS INC.

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

    • 9.5. Skye Biologics Holdings, LLC

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

    • 9.6. Smith & Nephew plc

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

      • 9.6.6. Business performance

    • 9.7. Stryker Corporation.

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

      • 9.7.7. Key strategic moves and developments

    • 9.8. Tissue Regenix Group Plc

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. ConvaTec Group plc

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

      • 9.9.7. Key strategic moves and developments

    • 9.10. Lavior Pharma Inc.

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

  • LIST OF TABLES

  • TABLE 01. GLOBAL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 02. WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2022-2032 ($MILLION)
    TABLE 03. GLOBAL BIOLOGICAL SKIN SUBSTITUTES WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
    TABLE 04. WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2022-2032 ($MILLION)
    TABLE 05. GLOBAL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 06. WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY REGION, 2022-2032 ($MILLION)
    TABLE 07. GLOBAL ACUTE WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
    TABLE 08. WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY REGION, 2022-2032 ($MILLION)
    TABLE 09. GLOBAL CHRONIC WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
    TABLE 10. GLOBAL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 11. WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
    TABLE 12. WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY REGION, 2022-2032 ($MILLION)
    TABLE 13. WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
    TABLE 14. WOUND CARE BIOLOGICS MARKET, BY REGION, 2022-2032 ($MILLION)
    TABLE 15. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 16. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 17. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 18. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
    TABLE 19. U.S. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 20. U.S. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 21. U.S. WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 22. CANADA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 23. CANADA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 24. CANADA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 25. MEXICO WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 26. MEXICO WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 27. MEXICO WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 28. EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 29. EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 30. EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 31. EUROPE WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
    TABLE 32. GERMANY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 33. GERMANY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 34. GERMANY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 35. FRANCE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 36. FRANCE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 37. FRANCE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 38. UK WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 39. UK WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 40. UK WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 41. ITALY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 42. ITALY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 43. ITALY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 44. SPAIN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 45. SPAIN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 46. SPAIN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 47. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 48. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 49. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 50. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 51. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 52. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 53. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
    TABLE 54. JAPAN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 55. JAPAN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 56. JAPAN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 57. CHINA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 58. CHINA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 59. CHINA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 60. INDIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 61. INDIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 62. INDIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 63. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 64. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 65. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 66. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 67. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 68. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 69. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 70. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 71. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 72. LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 73. LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 74. LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 75. LAMEA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
    TABLE 76. BRAZIL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 77. BRAZIL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 78. BRAZIL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 79. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 80. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 81. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 82. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 83. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 84. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 85. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
    TABLE 86. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
    TABLE 87. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
    TABLE 88. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
    TABLE 89. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
    TABLE 90. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
    TABLE 91. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
    TABLE 92. KERECIS: KEY EXECUTIVES
    TABLE 93. KERECIS: COMPANY SNAPSHOT
    TABLE 94. KERECIS: PRODUCT SEGMENTS
    TABLE 95. KERECIS: PRODUCT PORTFOLIO
    TABLE 96. MIMEDX GROUP, INC.: KEY EXECUTIVES
    TABLE 97. MIMEDX GROUP, INC.: COMPANY SNAPSHOT
    TABLE 98. MIMEDX GROUP, INC.: PRODUCT SEGMENTS
    TABLE 99. MIMEDX GROUP, INC.: PRODUCT PORTFOLIO
    TABLE 100. MIMEDX GROUP, INC.: KEY STRATERGIES
    TABLE 101. ORGANOGENESIS HOLDINGS INC.: KEY EXECUTIVES
    TABLE 102. ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT
    TABLE 103. ORGANOGENESIS HOLDINGS INC.: PRODUCT SEGMENTS
    TABLE 104. ORGANOGENESIS HOLDINGS INC.: PRODUCT PORTFOLIO
    TABLE 105. SKYE BIOLOGICS HOLDINGS, LLC: KEY EXECUTIVES
    TABLE 106. SKYE BIOLOGICS HOLDINGS, LLC: COMPANY SNAPSHOT
    TABLE 107. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT SEGMENTS
    TABLE 108. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT PORTFOLIO
    TABLE 109. SMITH & NEPHEW PLC: KEY EXECUTIVES
    TABLE 110. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
    TABLE 111. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
    TABLE 112. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
    TABLE 113. STRYKER CORPORATION.: KEY EXECUTIVES
    TABLE 114. STRYKER CORPORATION.: COMPANY SNAPSHOT
    TABLE 115. STRYKER CORPORATION.: PRODUCT SEGMENTS
    TABLE 116. STRYKER CORPORATION.: PRODUCT PORTFOLIO
    TABLE 117. STRYKER CORPORATION.: KEY STRATERGIES
    TABLE 118. TISSUE REGENIX GROUP PLC: KEY EXECUTIVES
    TABLE 119. TISSUE REGENIX GROUP PLC: COMPANY SNAPSHOT
    TABLE 120. TISSUE REGENIX GROUP PLC: PRODUCT SEGMENTS
    TABLE 121. TISSUE REGENIX GROUP PLC: PRODUCT PORTFOLIO
    TABLE 122. CONVATEC GROUP PLC: KEY EXECUTIVES
    TABLE 123. CONVATEC GROUP PLC: COMPANY SNAPSHOT
    TABLE 124. CONVATEC GROUP PLC: PRODUCT SEGMENTS
    TABLE 125. CONVATEC GROUP PLC: PRODUCT PORTFOLIO
    TABLE 126. CONVATEC GROUP PLC: KEY STRATERGIES
    TABLE 127. LAVIOR PHARMA INC.: KEY EXECUTIVES
    TABLE 128. LAVIOR PHARMA INC.: COMPANY SNAPSHOT
    TABLE 129. LAVIOR PHARMA INC.: PRODUCT SEGMENTS
    TABLE 130. LAVIOR PHARMA INC.: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 01. WOUND CARE BIOLOGICS MARKET, 2022-2032
    FIGURE 02. SEGMENTATION OF WOUND CARE BIOLOGICS MARKET, 2022-2032
    FIGURE 03. WOUND CARE BIOLOGICS MARKET,2022-2032
    FIGURE 04. TOP INVESTMENT POCKETS IN WOUND CARE BIOLOGICS MARKET (2023-2032)
    FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
    FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
    FIGURE 07. MODERATE THREAT OF SUBSTITUTES
    FIGURE 08. MODERATE INTENSITY OF RIVALRY
    FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
    FIGURE 10. GLOBAL WOUND CARE BIOLOGICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022(%)
    FIGURE 12. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY COUNTRY 2022-2032(%)
    FIGURE 13. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY COUNTRY 2022-2032(%)
    FIGURE 14. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022(%)
    FIGURE 15. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY COUNTRY 2022-2032(%)
    FIGURE 16. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY COUNTRY 2022-2032(%)
    FIGURE 17. WOUND CARE BIOLOGICS MARKET, BY   END USER, 2022(%)
    FIGURE 18. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022-2032(%)
    FIGURE 19. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY COUNTRY 2022-2032(%)
    FIGURE 20. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022-2032(%)
    FIGURE 21. WOUND CARE BIOLOGICS MARKET BY REGION, 2022
    FIGURE 22. U.S. WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 23. CANADA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 24. MEXICO WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 25. GERMANY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 26. FRANCE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 27. UK WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 28. ITALY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 29. SPAIN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 30. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 31. JAPAN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 32. CHINA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 33. INDIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 34. AUSTRALIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 35. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 36. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 37. BRAZIL WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 38. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 39. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 40. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
    FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 45. COMPETITIVE DASHBOARD
    FIGURE 46. COMPETITIVE HEATMAP: WOUND CARE BIOLOGICS MARKET
    FIGURE 47. TOP PLAYER POSITIONING, 2022
    FIGURE 48. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 50. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 51. MIMEDX GROUP, INC.: NET SALES, 2020-2022 ($MILLION)
    FIGURE 52. ORGANOGENESIS HOLDINGS INC.: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 53. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 54. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 55. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 56. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 57. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 58. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 59. TISSUE REGENIX GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 60. TISSUE REGENIX GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 61. CONVATEC GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 62. CONVATEC GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 63. CONVATEC GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of wound care biologics market is $1,786.50 million in 2022.

A. The forecast period for wound care biologics market is 2023 to 2032.

A. The market value of wound care biologics market in 2032 is $3,249.14 million.

A. The base year is 2022 in wound care biologics market.

A. The biological skin substitutes segment is the most influencing segment in wound care biologics market owing to high adoption of biological skin substitutes as they offer benefits such as faster wound closure, reduced infection risk, and improved outcomes.

A. Integra LifeSciences Holdings Corporation, Smith & Nephew plc, Stryker Corporation., MIMEDX Group, Inc., and ConvaTec Group plc held a high market position in 2022. These key players held a high market position owing to the strong geographical foothold in North America, Europe, Asia-Pacific, and LAMEA.

A. Wound care biologics are commonly used for chronic and non-healing wounds, such as diabetic foot ulcers, venous ulcers, and pressure ulcers. They may also be used in burns and surgical wounds to enhance healing and minimize scarring.

A. Wound care biologics are medical products derived from living organisms or substances that are used to promote wound healing and tissue regeneration. They may include growth factors, cytokines, extracellular matrix components, or stem cells.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Wound Care Biologics Market

Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jul 2024 - Jul 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2024 - Jul 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2024 - Jul 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2024 - Jul 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2024 - Jul 2025)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers